ArticleCureus2026
Dimethylarginine Dimethylaminohydrolase 1 (DDAH1)-Arginine Metabolic Axis Is Independently Associated With Alzheimer's Disease Risk in the UK Biobank.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Altered arginine metabolism and nitric oxide (NO) signaling have been implicated in Alzheimer's disease (AD), but the role of dimethylarginine dimethylaminohydrolase 1 (DDAH1), a regulator of nitric oxide bioavailability, remains unclear. We investigated whether the DDAH1-arginine metabolic axis is independently associated with AD risk in the UK Biobank (UKB). Methods We analyzed 50,988 UK Biobank participants with available proteomic, metabolomic, clinical, genetic, and neuroimaging data. Plasma DDAH1 levels were measured using the Olink Explore 3072 platform (Olink Proteomics AB, Uppsala, Sweden). Associations between DDAH1, circulating arginine, and AD were evaluated using multivariable logistic regression adjusted for age, sex, education, APOE ε4 dosage, and genetic principal components. Interaction analyses assessed whether DDAH1 modified the association between arginine and AD risk. Structural MRI phenotypes were examined using multivariable linear regression. Results DDAH1 levels were significantly elevated in AD cases in unadjusted analyses (p = 0.001). Higher systemic arginine was independently associated with lower AD risk (odds ratio {OR} = 0.604; p = 0.0033). A significant DDAH1-arginine interaction persisted after multivariable adjustment (OR = 1.431; p = 0.000108), indicating that the association between arginine and AD differed according to DDAH1 expression. Most MRI phenotypes were not significantly associated with DDAH1, although reduced hippocampal volume was observed in a neuroimaging subset. Conclusions The DDAH1-arginine metabolic axis is independently associated with AD risk and may represent a biologically relevant pathway linking nitric oxide dysregulation to neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.